ACR Congress Review 2019

adalimumab use in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate: 26-week
analysis of a phase 3 study. Arthritis Rheumatol. 2019; 71 (suppl 10):A1375.
Fleischmann R, Enejosa J, Song I, Mysler E, Bessette L, Peterfy C, Durez P, Östör A, Zhou Y, Genovese M. Safety and effectiveness of
upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 48 weeks. Arthritis Rheumatol. 2019; 71 (suppl 10):A527.
Fleischmann R, Genovese M, Blanco R, Hall S, Thomson G, Van den Bosch F, Zerbini C, Enejosa J, Li Y, DeMasi R, Song I. Clinical and
functional outcomes among rheumatoid arthritis patients switching between JAK1-selective inhibitor upadacitinib and adalimumab following
insufficient response. Arthritis Rheumatol. 2019; 71 (suppl 10):A2907.
Frank-Bertoncelj M, Distler O, Killeen T, Kwok K, Wang L, Ospelt C, Ciurea A. joint-specific responses to tofacitinib and methotrexate in
rheumatoid arthritis: a post hoc analysis of data from ORAL. Arthritis Rheumatol. 2019; 71 (suppl 10):A1338.
Genovese M, de Vlam K, Gottenberg J, Bartok B, Tiamiyu I, Guo Y, Tasset C, Sundy J, Walker D, Takeuchi T, Kalunian K. A subgroup
analysis of clinical efficacy response and quality of life outcomes from phase 3 study of filgotinib in patients with inadequate response to
biologic DMARDs. Arthritis Rheumatol. 2019; 71 (suppl 10):A517.
Genovese M, Kalunian K, Gottenberg J, Bartok B, Tan Y, Guo Y, Tasset C, Sundy J, de Vlam K, Walker D, Takeuchi T. Effects of filgotinib
on anemia, thrombocytopenia and leukopenia: results from a phase 3 study in patients with active rheumatoid arthritis and prior inadequate
response or intolerance to biological DMARDs. Arthritis Rheumatol. 2019; 71 (suppl 10):A2875.
Genovese M, Smolen J, Takeuchi T, Burmester G, Brinker D, Rooney T, Zhong J, Mo D, Saifan C, Cardoso A, Issa M, Wu W, Winthrop K.
Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. Arthritis Rheumatol.
2019; 71 (suppl 10):A847.
Genovese M, Weinblatt M, Wu J, Jia B, Quebe A, Sun L, Chen Y, Helt C, Bacani A, Reis P, Pope J. Patient disease trajectories in
baricitinib-2 mg-treated patients with rheumatoid arthritis and inadequate response to biologic DMARDs. Arthritis Rheumatol. 2019; 71
(suppl 10):A1350.
Hall S, Takeuchi T, Thomson G, Emery P, Combe B, Everding A, Pavelka K, Song Y, Shaw T, Friedman A, Song I, Mysler E.
Characterization of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators. Arthritis Rheumatol. 2019; 71
(suppl 10):A529.
Harnett J, Smith T, Woolcott J, Gruben D, Murray C. Impact of TNF inhibitor cycling with adalimumab and etanercept vs switching to
tofacitinib. Arthritis Rheumatol. 2019; 71 (suppl 10):A1426.
Ismail M, Nader A, Winzenborg I, Song I, Othman A. Exposure-response analyses for upadacitinib efficacy and safety in ankylosing
spondylitis – analyses of the SELECT-AXIS I study. Arthritis Rheumatol. 2019; 71 (suppl 10):A1492.
Kalunian K, Genovese M, Gottenberg J, Bartok B, Pechonkina A, Guo Y, Tasset C, Sundy J, de Vlam K, Walker D, Takeuchi T. A subgroup
analysis of the efficacy of filgotinib in demographic and clinical subgroups of patients with refractory rheumatoid arthritis. Arthritis
Rheumatol. 2019; 71 (suppl 10):A504.
Kapetanovic M, Andersson M, Friedman A, Shaw T, Song Y, Aletaha D, Buch M, Müller-Ladner U, Pope J. Efficacy and safety of
upadacitinib monotherapy in MTX-naïve patients with early active RA receiving treatment within 3 months of diagnosis: a post-hoc analysis
of the SELECT-EARLY. Arthritis Rheumatol. 2019; 71 (suppl 10):A512.
Karpes A, Duan Z, Zhao H, Lal L, Chan W, Suárez-Almazor M, Giordano S, Swint J, Lopez-Olivo M. Treatment sequences, effectiveness,
and costs of tumor necrosis factor inhibitor cycling compared with swapping to a novel disease-modifying anti-rheumatic drug in rheumatoid
arthritis patients. Arthritis Rheumatol. 2019; 71 (suppl 10):A252.
Kavanaugh A, Westhovens R, Winthrop K, Lee S, Greer J, DeZure A, An D, Ye L, Sundy J, Besuyen R, Meuleners L, Alten R, Genovese
M. Rheumatoid arthritis treatment with filgotinib: week 156 safety and efficacy data from a phase 2b open-label extension study. Arthritis
Rheumatol. 2019; 71 (suppl 10):A550.
Ki S, Kim D, Lee J, Moon B, Ryu S. Identification of CJ-15314, a novel highly selective JAK1 inhibitor, for the treatment of rheumatoid
arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A992.
Kirkham B, Nikiphorou E, López-Romero P, Kouris I, Holzkaemper T, Zaremba-Pechmann L, de la Torre I, Taylor P. Effect of baricitinib on
functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs. Arthritis
Rheumatol. 2019; 71 (suppl 10):A1439.
Kremer J, Bingham C, Cappelli L, Greenberg J, Geier J, Madsen A, Chen C, Onofrei A, Barr C, Pappas D, Litman H, Dandreo K, Shapiro
A, Connell C, Kavanaugh A. Post-approval comparative safety study of tofacitinib and biologic DMARDS: five‐year results from a US-based
rheumatoid arthritis registry. Arthritis Rheumatol. 2019; 71 (suppl 10):A2372.
Kremer J, Bingham C, Cappelli L, Greenberg J, Madsen A, Geier J, Rivas J, Onofrei A, Barr C, Pappas D, Litman H, Dandreo K, Shapiro A,
Connell C, Kavanaugh A. Comparison of malignancy and mortality rates between tofacitinib and biologic DMARDS in clinical practice: fiveyear
results from a US-based rheumatoid arthritis registry. Arthritis Rheumatol. 2019; 71 (suppl 10):A2874.
*Chairman’s Pick